Immunovaccine’s DepoVax™ Technology Underpins New Experimental Therapy for Cervical, Head and Neck Cancers

IMV vaccine adjuvant technology of choice For Dana-Farber’s HPV-related cancer clinical trial  April 8, 2014 Immunovaccine Inc., a clinical stage vaccine company, today announced that its DepoVax™ adjuvanting technology will underlie the design of a new cancer vaccine trial that will be conducted by the Dana-Farber Cancer Institute to treat cervical and head and neck cancer. In a competitive process, …